GLP-1 Drug Costs and Access: Insurance, Compounding, and Affordability in 2026

A $1,349 Monthly Price Tag and the System Behind It

Wegovy injections and pills carry a list price of $1,349 per month. Ozempic runs over $1,000. Zepbound sits in the same range. These are the numbers your pharmacy sees before insurance or coupons get applied.

List price is misleading, though. Think of it like a car sticker price: almost nobody pays it, but the entire negotiation system revolves around it. The actual net prices that insurers pay, after confidential rebates from manufacturers, land somewhere between $8,000 and $9,000 per year in the US commercial market. That still translates to roughly $670-$750 per month flowing through the insurance system for each patient.

Now compare those numbers to what other countries pay. At a congressional hearing, legislators pointed out that Wegovy's annual net price runs approximately $2,232 in Denmark (where Novo Nordisk is headquartered), $1,680 in Germany, and $1,104 in the United Kingdom. Americans pay four to eight times more for the same molecule.

Patent protection explains part of it. GLP-1 manufacturers have built dense patent portfolios: a median of 19.5 patents per GLP-1 drug with 18.3 years of expected protection, according to ICER's analysis. More than half those patents cover delivery devices, not the active ingredients themselves. Tirzepatide patents won't expire until around 2036, meaning generic competition is still a decade away.

Demand compounds the pricing problem. Over 40% of US adults have obesity, translating to more than 100 million potential GLP-1 users. Roughly 12% of Americans, about 40 million people, have already used a GLP-1 for weight loss. And 56% of GLP-1 users report the drugs were difficult to afford, with one in four calling them "very difficult" to afford.

Novo Nordisk announced in February 2026 that it will cut list prices for Ozempic, Rybelsus, and Wegovy to $675 per month, effective January 1, 2027. For people in high-deductible plans or paying coinsurance (where costs are a percentage of list price), that matters. But $675 is still triple what Denmark pays. If you are paying cash without insurance today, the price that actually matters to you is the direct-to-consumer rate, which runs $349 to $499 per month depending on the medication and where you buy it.

Medicare's $50 Copay Experiment: What the GLP-1 Bridge Actually Covers

Medicare has been legally barred from covering drugs prescribed for weight loss since Part D launched. A 65-year-old taking Wegovy for obesity? Full cash price. The same drug prescribed for cardiovascular risk reduction? Covered by Part D. Same molecule, different indication, wildly different cost.

That absurdity changes in July 2026. The Centers for Medicare and Medicaid Services announced the Medicare GLP-1 Bridge, a short-term demonstration running from July 1 through December 31, 2026. Eligible beneficiaries will pay a $50 monthly copayment for Wegovy (injection and tablets) and Zepbound when prescribed for weight reduction.

The eligibility criteria are tighter than many people realize. You need to meet one of three tiers based on your BMI at the time you started GLP-1 therapy, not your current BMI: a BMI of 35 or higher on its own; BMI of 30 or higher with heart failure, uncontrolled hypertension, or chronic kidney disease stage 3a or above; or BMI of 27 or higher with prediabetes, previous heart attack, previous stroke, or symptomatic peripheral artery disease.

Here is where it gets tricky. The bridge program operates outside the Part D benefit entirely. Your $50 monthly copayment will not count toward the Part D deductible or the $2,100 out-of-pocket spending cap. If you qualify for the Part D Low-Income Subsidy, those cost-sharing reductions do not apply to bridge program prescriptions. For low-income beneficiaries, $50 per month may be a barrier rather than a benefit.

Behind the scenes, participating manufacturers agreed to provide these drugs at a net price of $245 per monthly supply. CMS is using Humana, the current administrator of the LI NET program, as the central processor for prior authorization and claims.

What happens after December 2026 is where things get complicated. The BALANCE Model launches in January 2027 as a longer-term demonstration. Unlike the bridge, BALANCE is voluntary for Part D plans. Both Novo Nordisk and Eli Lilly have agreed to participate, and the model will cover all formulations of Mounjaro, Ozempic, Rybelsus, Wegovy, the Zepbound KwikPen, and potentially orforglipron if the FDA approves it. Cost sharing under BALANCE will be $50 per month for enhanced plans and $125 per month for basic plans, with medications dropping to $0 after reaching the $2,400 out-of-pocket maximum in 2027.

Separately, semaglutide (Ozempic, Wegovy, Rybelsus) was selected for Medicare drug price negotiation in 2025, with the negotiated maximum fair price taking effect January 1, 2027. This operates independently from the bridge and BALANCE programs and will set a ceiling on what Medicare pays going forward.

Medicare beneficiaries: verify that your Part D plan will participate in the BALANCE Model for 2027 during open enrollment. If it does not, your GLP-1 coverage for obesity ends December 31, 2026.

Why Your Employer Might Drop GLP-1 Coverage This Year

The 2025 KFF Employer Health Benefits Survey captures a pattern: rapid adoption, then sticker shock. 43% of firms with 5,000 or more workers covered GLP-1 drugs for weight loss in 2025, up from 28% just one year earlier. But 59% of those same large firms reported higher-than-expected use, and 66% said the coverage had a significant impact on their prescription drug spending.

The cost pressure is hard to overstate. Blue Cross Blue Shield of Massachusetts ended 2024 with a $400 million operating loss, its worst financial performance on record, with GLP-1 drugs as the single largest driver, accounting for more than $300 million, or 20% of the insurer's total pharmacy costs. Colorado's spending on GLP-1s for state workers quadrupled from 2023 to 2024 and was doubling every six months. North Carolina's state employee health plan calculated that it would need to double its insurance premium to keep covering GLP-1s for obesity.

KFF ran focus groups with over 100 companies, and the quotes are striking. One HR director described GLP-1s going from "#32 to #1" in pharmacy spending within a single year. Another firm that started covering them watched projected costs jump from $500,000 to $1.2 million. Multiple companies reported pulling coverage entirely.

Employers that still cover GLP-1s are increasingly adding gatekeeping requirements. 34% of covering firms now require enrollees to participate in lifestyle or clinical support programs before getting coverage, up from just 10% the prior year. Others are tightening BMI thresholds, mandating step therapy with older (cheaper) weight-loss medications first, or restricting coverage to diabetes diagnoses only.

One wrinkle several employers mentioned: employees who want GLP-1s for weight loss are getting diagnosed with diabetes even when they may not fully meet the diagnostic criteria. HR leaders described tightening authorization processes specifically because GLP-1 prescriptions for diabetics seemed suspiciously high.

If your employer does cover GLP-1s for weight loss, confirm the current rules. Check whether your plan requires prior authorization, step therapy, a minimum BMI threshold, or participation in a lifestyle program. These requirements change at least annually, and what worked last year may not work now. If your employer drops coverage, manufacturer savings programs and direct-to-consumer options become your primary path, which the next section covers.

Savings Cards, Cash Programs, and the $149 Wegovy Pill

Both Novo Nordisk and Eli Lilly now sell directly to patients, bypassing insurers. The gap between what you could pay ($25) and what you might pay ($1,349) is enormous, and it comes down to knowing which programs exist.

For Wegovy, the NovoCare Savings Offer brings commercially insured patients down to as low as $25 per month, subject to a maximum savings of $100 per month. The catch: government insurance beneficiaries (Medicare, Medicaid, Tricare) cannot use it. If you have commercial insurance that covers Wegovy at all, this card can reduce your out-of-pocket cost significantly.

For patients paying cash, Novo Nordisk launched NovoCare Pharmacy, offering the Wegovy pill at $149 per month for the 1.5 mg and 4 mg doses. The introductory price for new patients on starting doses (0.25 mg and 0.5 mg) runs $199 per month for the first two fills. Injectable Wegovy and most Ozempic dosages dropped to $349 per month when purchased directly from the manufacturer, telehealth partners, or retail pharmacies. Eli Lilly's LillyDirect offers a similar cash-pay program for Zepbound.

The Trump administration's TrumpRx platform, announced in November 2025, is intended to offer Ozempic, Wegovy, and Zepbound at roughly $350 per month through a direct-to-consumer model. The oral Wegovy pill could cost approximately $150 per month through this platform. These prices are still subject to change and dose-dependent.

For people who still cannot afford these prices, patient assistance programs exist. Novo Nordisk's Patient Assistance Program provides free medications to qualifying uninsured patients below certain income thresholds. Eli Lilly runs a similar program for Zepbound. Eligibility typically requires proof of income and lack of insurance coverage for the medication.

A Navitus Health Solutions survey of nearly 2,000 GLP-1 users found that 7 in 10 said cost influenced their decision to start or continue treatment, and 1 in 4 paid more than $250 per prescription fill. The savings programs above can change those numbers, but they require you to actually apply.

The Compounding Crackdown: 1,150 Adverse Events and Counting

Compounded semaglutide and tirzepatide filled a real gap during the 2023-2024 drug shortages, when brand-name versions were genuinely unavailable. The FDA allowed compounding pharmacies to produce these drugs because they appeared on the official shortage list. At their peak, over 2 million Americans were receiving compounded GLP-1 drugs, mostly through telehealth companies selling them at a fraction of the brand-name price.

That legal foundation has since eroded. The FDA removed tirzepatide from its shortage list in October 2024 and semaglutide in February 2025. Once a drug is no longer in shortage, compounders lose their authorization to produce versions that are identical or nearly identical to the approved product.

The adverse event data is sobering. As of July 31, 2025, the agency had received 605 adverse event reports for compounded semaglutide and 545 for compounded tirzepatide. These numbers are almost certainly undercounted: federal law does not require state-licensed pharmacies (that are not outsourcing facilities) to report adverse events to the FDA.

The issues are not just about volume. The FDA has documented specific risks with compounded GLP-1s: dosing errors that caused hospitalizations, products arriving warm without adequate refrigeration, fraudulent labels listing pharmacies that did not actually compound the products, and the use of semaglutide salt forms (semaglutide sodium, semaglutide acetate) that are different active ingredients from what is in the approved drugs. The FDA has stated plainly that it does not have information on whether these salts have the same chemical and pharmacologic properties.

The agency has also established import alert 66-80 to intercept GLP-1 active pharmaceutical ingredients with quality concerns at the US border. And two compounds that some pharmacies were starting to offer, retatrutide and cagrilintide, cannot legally be compounded at all because they are not components of any FDA-approved drug.

To be clear: compounding itself is not the problem. Legitimate compounding pharmacies serve patients who need doses that are not commercially available, or who react to an inactive ingredient in the branded version. What went wrong with GLP-1 compounding is scale. The market grew far beyond individual patient needs, driven by cost, not medical necessity. And the telehealth companies distributing these products operated with minimal oversight.

Telehealth Prescribers Under Fire: 30 Warning Letters and a Lawsuit

On March 3, 2026, the FDA issued 30 warning letters to telehealth companies for making false or misleading claims about compounded GLP-1 products. FDA Commissioner Marty Makary called it "a new era," stating that the agency sent thousands of warning letters over the past six months, more than had been sent over the entire preceding decade.

The primary violations: telehealth companies were making claims implying their products were the same as FDA-approved medications and obscuring product sourcing by branding drugs with the telehealth firm's name, making it appear they were the compounder when they were not.

Novo Nordisk has gone further, suing Hims & Hers directly over compounded GLP-1 sales. The company's general counsel told USA Today the lawsuit should put other telehealth companies "on notice."

The telehealth GLP-1 market spans a wide range. Companies like Calibrate built programs around board-certified physicians, metabolic health panels, and structured lifestyle coaching with FDA-approved medications. Other platforms were offering compounded injections after a quick questionnaire, with no lab work and no ongoing clinical relationship. The FDA crackdown targets the latter, but the regulatory pressure touches everyone.

If you are currently getting a compounded GLP-1 through a telehealth provider, talk to your prescriber about a transition plan now. Many legitimate telehealth platforms are transitioning patients to FDA-approved medications, often at the manufacturer cash-pay prices of $349-$499 per month through LillyDirect or NovoCare Pharmacy. Others are pivoting to prescribing older, less expensive weight-loss medications. Losing access abruptly is risky. Weight regain after stopping GLP-1s is well documented, and an unplanned gap in treatment can undo months of progress.

Seven Ways to Actually Lower Your GLP-1 Costs

GLP-1 affordability is a long-term budgeting problem, not a one-time expense. More than half of GLP-1 users stop within six months, most often because of cost, and only 14.3% remain on therapy at two years. Building a sustainable payment approach matters more than finding the cheapest option for month one.

Strategy	Who It Helps	Potential Monthly Cost
Manufacturer savings card (Wegovy, Zepbound)	Commercially insured patients	$25-$150
NovoCare Pharmacy / LillyDirect cash pay	Anyone without government insurance	$149-$499
Medicare GLP-1 Bridge (July-Dec 2026)	Medicare Part D enrollees meeting BMI criteria	$50
TrumpRx platform	General public (pending launch details)	$150-$350
Patient Assistance Programs	Low-income, uninsured patients	$0
Oral Wegovy pill (25 mg tablet)	Anyone preferring pills over injections	$149-$199 (cash)
Employer insurance appeal / exception request	Employees whose plans exclude weight loss	Varies by plan

1. Stack manufacturer savings with insurance. If your commercial insurance covers GLP-1s at all, apply for the manufacturer savings card before your first fill. Wegovy's card can drop your copay to $25. Zepbound's savings program works similarly. These cannot be used with Medicare, Medicaid, or other government insurance.

2. Compare pills versus injections. The Wegovy tablet (25 mg, taken daily) and the injectable pen serve the same purpose, but pricing differs. Through NovoCare Pharmacy, the pill starts at $149 per month for cash-pay patients on the 1.5 mg dose. If you are needle-averse or price-sensitive, the pill may be the better option financially.

3. Request a formulary exception. If your insurance covers GLP-1s for diabetes but not weight loss, ask your doctor to submit a formulary exception request. Document comorbidities like cardiovascular disease, sleep apnea, or prediabetes that might qualify for a covered indication. This does not always work, but it costs nothing to try.

4. Check whether your employer plan is adding or dropping coverage. Coverage is shifting year to year. Ask your benefits department during open enrollment. Some employers are adding GLP-1 coverage with new gatekeeping requirements (lifestyle programs, BMI thresholds); others are removing it entirely.

5. Time your Medicare enrollment carefully. If you are approaching 65 or already on Medicare, watch for BALANCE Model participation announcements in mid-2026. You will need to enroll in a Part D plan that participates in BALANCE to maintain GLP-1 coverage for obesity after the bridge program ends in December 2026.

6. Use patient assistance if you qualify. Both Novo Nordisk and Eli Lilly offer free medication to patients below income thresholds who lack insurance coverage. Contact NovoCare (1-888-809-3942) or LillyDirect for eligibility screening.

7. Build the cost into your long-term health budget. GLP-1 therapy is not a short-term intervention. People who stop taking them typically regain the weight they lost. Factor the medication cost into your monthly budget the same way you would a car payment or rent increase, and explore whether the savings from reduced costs of other medications (blood pressure, cholesterol, diabetes) offset some of the GLP-1 expense over time.

Frequently Asked Questions

Does Medicare cover GLP-1 drugs for weight loss in 2026?

Starting July 1, 2026, the Medicare GLP-1 Bridge program will provide coverage for Wegovy and Zepbound at a $50 monthly copayment for beneficiaries who meet specific BMI and clinical criteria. This is a temporary program running through December 31, 2026. For continued coverage in 2027, you will need to enroll in a Part D plan that participates in the BALANCE Model. Medicare Part D plans continue to cover GLP-1s for approved non-obesity uses like type 2 diabetes and cardiovascular risk reduction regardless of the bridge program.

Are compounded semaglutide and tirzepatide still legal?

The legal basis for compounding these drugs narrowed significantly after the FDA removed both from the drug shortage list (tirzepatide in October 2024, semaglutide in February 2025). Compounding pharmacies can still produce these medications for patients with specific needs that cannot be met by the approved versions, but they can no longer produce versions that are identical or nearly identical to the brand-name drugs. The FDA is actively enforcing against telehealth companies marketing compounded GLP-1s. Litigation challenging the FDA's shortage determinations is ongoing.

What is the cheapest way to get a GLP-1 drug right now?

For commercially insured patients, manufacturer savings cards can bring costs as low as $25 per month. For cash-pay patients, the Wegovy pill through NovoCare Pharmacy starts at $149 per month. For Medicare beneficiaries, the GLP-1 Bridge will offer a $50 copay starting July 2026. Uninsured patients below income thresholds may qualify for free medication through manufacturer patient assistance programs.

Will GLP-1 drug prices keep dropping?

Several forces are pushing prices down. Novo Nordisk's list price cut to $675 takes effect January 2027. Medicare's negotiated price for semaglutide also takes effect in 2027. Competition from newer GLP-1 drugs and potential oral formulations like orforglipron should add further pressure. Generic competition remains distant: tirzepatide patents run through approximately 2036.

Should I switch from a compounded GLP-1 to a brand-name version?

If you are on a compounded GLP-1, discuss a transition plan with your prescriber. The FDA has documented over 1,100 adverse event reports associated with compounded semaglutide and tirzepatide, including dosing errors and quality issues. Brand-name versions are now more accessible at lower cash-pay prices ($149-$499 per month) than when the compounding market first expanded. The regulatory environment is tightening, and compounded availability may decrease further.